A study to understand how well DC806 works and how safe it is in participants with plaque psoriasis
- Conditions
- Plaque PsoriasisMedDRA version: 20.0Level: PTClassification code: 10037153Term: Psoriasis Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Registration Number
- CTIS2022-502249-90-00
- Lead Sponsor
- DICE Therapeutics Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 315
• Male or female, 18 to 70 years of age, inclusive • Body mass index (BMI) of 18 to 40 kg/m2 • All of the following psoriasis criteria: o Clinical diagnosis of plaque psoriasis for =6 months before the Baseline visit o Stable moderate to severe chronic plaque psoriasis, defined as =10% BSA psoriasis involvement, sPGA score of =3, and PASI score =12 at the Screening and Baseline visits o Candidate for phototherapy or systemic therapy, as assessed by the Investigator • Women of childbearing potential (WOCBP) must be willing to use a highly effective method of contraception during the study and for =30 days after the last dose of study drug • Willing to discontinue topical and/or systemic therapies for psoriasis before the first dose of study drug
• Have had a clinically significant flare of psoriasis during the 12 weeks before the Baseline visit, as assessed by the Investigator • History of erythrodermic psoriasis, generalized or localized pustular psoriasis, predominantly guttate psoriasis, medication-induced or medication-exacerbated psoriasis • History of chronic infections including human immunodeficiency virus (HIV) or viral hepatitis (hepatitis B virus [HBV], hepatitis C virus [HCV]) • History of active tuberculosis (TB) • History or evidence of active infection (including but not limited to coronavirus disease 2019 [COVID-19] infection) and/or febrile illness within 14 days, serious infections leading to hospitalization and intravenous antibiotic treatment within 90 days, or serious infection requiring antibiotic treatment within 30 days before thefirst dose of study drug • History of malignancy or lymphoproliferative disease except resected cutaneous squamous cell or basal cell carcinoma that has been treated without recurrence • Presence of active suicidal ideation, or positive suicide behavior using the Baseline/Screening” version of the Columbia Suicide Severity Rating Scale (C-SSRS) and with either of the following criteria: o History of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt) within 5 years before the Screening visit o Suicidal ideation in the past month before the Screening visit as indicated by a positive response (Yes”) to either Question 4 or Question 5 of the Baseline/Screening” version of the C-SSRS • Participant has experienced primary failure (no response at approved doses after =3 months of therapy) to one or more therapeutic agents targeted to IL-17 (including but not limited to secukinumab, ixekizumab, brodalumab, bimekizumab) • Systemic use of known strong and moderate cytochrome P450 (CYP)3A4 inhibitors or strong CYP3A4 inducers from Screening through the end of the study • A 12-lead electrocardiogram (ECG) at Screening that demonstrates clinically significant abnormalities or criteria associated with QT interval abnormalities including prolongation of QT interval corrected for heart rateusing Fridericia’s formula (QTcF) (>500 msec) • Laboratory values meeting the following criteria within the screening period before the first dose of study drug: o Serum aspartate transaminase =2× upper limit of normal (ULN) o Serum alanine transaminase =2×ULN o Serum total, direct, or indirect bilirubin =2.0 mg/dL; except for participants with isolated elevation of indirect bilirubin relating to a confirmed diagnosis of Gilbert syndrome o Serum albumin 3.5 g/dL o Prothrombin time = 4 seconds or International Normalized Ratio ?1.7 o Estimated glomerular filtration rate (GFR) by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula <45 mL/min/1.73m2 o Total white blood cell count <3000/µL o Absolute neutrophil count <1500/µL o Platelet count <100,000/µL o Hemoglobin <9 g/dL • In the opinion of the Investigator or Sponsor, have any uncontrolled clinically significant laboratory abnormality that would affect interpretation of study data or the participant’s enrollment in the study
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: • To compare the efficacy of multiple doses of DC-806 versus placebo in adult participants with moderate to severe plaque psoriasis<br>• To compare the safety and tolerability of multiple doses of DC-806 versus placebo in adult participants with moderate to severe plaque psoriasis;Secondary Objective: • To compare the efficacy of various DC-806 dose regimens in adult participants with moderate to severe plaque psoriasis • To compare the efficacy of multiple doses of DC-806 versus placebo on additional efficacy endpoints in adult participants with moderate to severe plaque psoriasis • To assess the PK of DC-806 and intersubject variability in adult participants with moderate to severe plaque psoriasis;Primary end point(s): • Proportion of participants achieving =75% reduction in Psoriasis Area of Severity Index score (PASI-75) at Week 12 • Incidence proportion of TEAEs, SAEs, and TEAEs leading to discontinuation
- Secondary Outcome Measures
Name Time Method Secondary end point(s):• Proportion of participants in each DC-806 treatment group achieving PASI-75 at Week 12 • Proportion of participants achieving an sPGA score of 0 (clear) or 1 (almost clear) with =2 grade improvement from Baseline at Week 12;Secondary end point(s):• Proportion of participants achieving =50%, =75%, =90%, and 100% reduction in PASI score (PASI-50, PASI-75, PASI-90, and PASI-100, respectively) at all scheduled timepoints • Proportion of participants achieving an sPGA score of 0 or 1 at all scheduled timepoints;Secondary end point(s):• Change and percent change from Baseline in PASI score at all scheduled timepoints • Change and percent change from Baseline in the percentage of BSA affected at all scheduled timepoints • Measurement of plasma concentration of DC-806 at scheduled timepoints